Active, not recruitingNCT06916403

Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia

Studying Paraneoplastic neurologic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Wilderman Medical Clinic
Principal Investigator
Igor Wilderman, MD, MSW, LCSW
Wilderman Medical Clinic
Intervention
Intravenous Ketamine Infusions(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06916403 on ClinicalTrials.gov

Other trials for Paraneoplastic neurologic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Paraneoplastic neurologic syndrome

← Back to all trials